Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 15 September 2000:
Vol. 289. no. 5486, pp. 1857 - 1859
DOI: 10.1126/science.289.5486.1857
Prev | Table of Contents | Next

News of the Week

MOLECULAR BIOLOGY:
Cancer Fighter's Modus Operandi Revealed

Jean Marx

Researchers have deciphered how a promising cancer drug acts like a smart bomb, homing in on only a very narrow range of its potential targets in the cell. The compound, known as STI-571, has shown remarkable success in early clinical trials on patients with chronic myelogenous leukemia. Now, in work reported on page 1938, scientists reveal just how the compound works--information that could aid in the design of similar cancer therapies.

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Characterization of c-kit Expression in Small Cell Lung Cancer: Prognostic and Therapeutic Implications.
P. Micke, M. Basrai, A. Faldum, F. Bittinger, L. Ronnstrand, A. Blaukat, K. M. Beeh, F. Oesch, B. Fischer, R. Buhl, et al. (2003)
Clin. Cancer Res. 9, 188-194
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)